Status:
TERMINATED
Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit
Lead Sponsor:
Pfizer
Conditions:
Healthy
Eligibility:
FEMALE
18-55 years
Phase:
PHASE1
Brief Summary
To assess the effect of fesoterodine 8 mg as compared to solifenacin 10 mg on colonic transit.
Eligibility Criteria
Inclusion
- Healthy female subjects
Exclusion
- Evidence or history of clinically significant findings at screening
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00832650
Start Date
April 1 2009
End Date
December 1 2009
Last Update
December 24 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Rochester, Minnesota, United States, 55905